Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia

Nephrology

Volumn 16, Issue 8, 2011, Pages 697-703

  Shen, Wan Chen ^a   Chiang, Yi Chun ^a   Chen, Hsiang Yin ^a   Chen, Tso Hsiao ^a   Yu, Fang Lan ^b   Tang, Chao Hsiun ^a   Sue, Yuh Mou ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute kidney injury; Bacteraemia; Hospital cost; Staphylococcus aureus; Teicoplanin; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TEICOPLANIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HEALTH CARE COST; HUMAN; KAPLAN MEIER METHOD; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCAL BACTEREMIA;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HOSPITAL COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN;

EID: 84055176715     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01488.x     Document Type: Article

References (34)

1. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 2008;46(Suppl 5): S350-9. (Pubitemid 351717322)
2. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 2006;42:389-91. (Pubitemid 43122317)
3. EARSS annual report 2008. European Antimicrobial Resistance Surveillance System, 2008. [Cited 5 May 2011.] Available from URL: www.rivm.nl/earss/result/ Monitoring-reports
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 2003;36:53-9. (Pubitemid 36099097)
5. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med. 2006;34:700-6.
6. Gould FK, Brindle R, Chadwick PR et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother. 2009;63:849-61.
7. Griffith RS. Introduction to vancomycin. Rev. Infect. Dis. 1981;3(Suppl): S200-4.
8. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch. Intern. Med. 1989;149:1777-81. (Pubitemid 19200833)
9. Oktem F, Arslan MK, Ozguner F et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: Protection by erdosteine. Toxicology 2005;215:227-33. (Pubitemid 41446325)
10. Nishino Y, Takemura S, Minamiyama Y et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic. Res. 2003;37:373-9. (Pubitemid 36240400)
11. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin. Pharmacol. Toxicol. 2005;97:325-32. (Pubitemid 41608127)
12. Dieterich C, Puey A, Lin S et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol. Sci. 2009;107:258-69.
13. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents. Chemother. 2008;52:1330-6. (Pubitemid 351521995)
14. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch. Intern. Med. 2006;166:2138-44. (Pubitemid 44631403)
15. Kureishi A, Jewesson PJ, Rubinger M et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: Effect on cyclosporin A-associated nephrotoxicity. Antimicrob. Agents. Chemother. 1991;35:2246-52.
16. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin. Infect. Dis. 2002;34:1481-90. (Pubitemid 34553708)
17. D'Antonio D, Staniscia T, Piccolomini R et al. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: Microbiological, clinical and economic evaluation. Chemotherapy 2004;50:81-7. (Pubitemid 38813017)
18. Neville LO, Brumfitt W, Hamilton-Miller JM, Harding I. Teicoplanin vs. vancomycin for the treatment of serious infections: A randomised trial. Int. J. Antimicrob. Agents 1995;5:187-93.
19. Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J. Infect. Dis. 1994;169:350-5. (Pubitemid 24045595)
20. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: A prospective study. Am. J. Med. 1983;74:243-8. (Pubitemid 13192180)
21. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 2005;16:3365-70. (Pubitemid 46179340)
22. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care 2002;8:509-14. (Pubitemid 35388204)
23. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291:2328-34. (Pubitemid 38656299)
24. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15:85-91.
25. Elting LS, Rubenstein EB, Kurtin D et al. Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998;83:2597-607. (Pubitemid 29019582)
26. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 2004;8: R204-12.
27. Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: A comprehensive population-based study. J. Am. Soc. Nephrol. 2007;18:1292-8. (Pubitemid 46536915)
28. Hoste EA, Clermont G, Kersten A et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit. Care 2006;10: R73.
29. Akram AR, Singanayagam A, Choudhury G, Mandal P, Chalmers JD, Hill AT. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. Chest 2010;138:825-32.
30. Hata N, Yokoyama S, Shinada T et al. Acute kidney injury and outcomes in acute decompensated heart failure: Evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur. J. Heart. Fail. 2010;12:32-7.
31. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39:S1-266.
32. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis. Antimicrob. Agents. Chemother. 2009;53:4069-79.
33. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007;11:R31.
34. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 2009;49:325-7.